Won J, Lee P, Oh S. Alpha 2 adrenoceptor agonist guanabenz directly inhibits hyperpolarization-activated, cyclic nucleotide-modulated (HCN) channels in mesencephalic trigeminal nucleus neurons. Eur J Pharmacol. 2019;854:320-327 pubmed publisher

Malerba A, Roth F, Harish P, Dhiab J, Lu Nguyen N, Cappellari O, et al. Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy. Hum Mol Genet. 2019;28:1694-1708 pubmed publisher

Sun X, Aimé P, Dai D, Ramalingam N, Crary J, Burke R, et al. Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease. Exp Neurol. 2018;303:95-107 pubmed publisher

Jiang M, Liu L, He X, Wang H, Lin W, Wang H, et al. Regulation of PERK-eIF2? signalling by tuberous sclerosis complex-1 controls homoeostasis and survival of myelinating oligodendrocytes. Nat Commun. 2016;7:12185 pubmed publisher

Landeras Bueno S, Fernandez Y, Falcón A, Oliveros J, Ortin J. Chemical Genomics Identifies the PERK-Mediated Unfolded Protein Stress Response as a Cellular Target for Influenza Virus Inhibition. MBio. 2016;7:e00085-16 pubmed publisher

Vieira F, Ping Q, Moreno A, Kidd J, Thompson K, Jiang B, et al. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS. PLoS ONE. 2015;10:e0135570 pubmed publisher

Myers S, Andres K, Hagg T, Whittemore S. CD36 deletion improves recovery from spinal cord injury. Exp Neurol. 2014;256:25-38 pubmed publisher

Chen Y, Palczewska G, Mustafi D, Golczak M, Dong Z, Sawada O, et al. Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. J Clin Invest. 2013;123:5119-34 pubmed publisher

Konrad C, Queener S, Wek R, Sullivan W. Inhibitors of eIF2? dephosphorylation slow replication and stabilize latency in Toxoplasma gondii. Antimicrob Agents Chemother. 2013;57:1815-22 pubmed publisher

Ye H, Charpin El Hamri G, Zwicky K, Christen M, Folcher M, Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci U S A. 2013;110:141-6 pubmed publisher

Mockel A, Obringer C, Hakvoort T, Seeliger M, Lamers W, Stoetzel C, et al. Pharmacological modulation of the retinal unfolded protein response in Bardet-Biedl syndrome reduces apoptosis and preserves light detection ability. J Biol Chem. 2012;287:37483-94 pubmed publisher

Fullwood M, Zhou W, Shenolikar S. Targeting phosphorylation of eukaryotic initiation factor-2? to treat human disease. Prog Mol Biol Transl Sci. 2012;106:75-106 pubmed publisher

Tsaytler P, Bertolotti A. Exploiting the selectivity of protein phosphatase 1 for pharmacological intervention. FEBS J. 2013;280:766-70 pubmed publisher

Wainford R, Kapusta D. Functional selectivity of central G?-subunit proteins in mediating the cardiovascular and renal excretory responses evoked by central ?(2) -adrenoceptor activation in vivo. Br J Pharmacol. 2012;166:210-20 pubmed publisher

Voisset C, Saupe S, Blondel M. The various facets of the protein-folding activity of the ribosome. Biotechnol J. 2011;6:668-73 pubmed publisher

Reis S, Pang Y, Vishnu N, Voisset C, Galons H, Blondel M, et al. Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie. 2011;93:1047-54 pubmed publisher

Tsaytler P, Harding H, Ron D, Bertolotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011;332:91-4 pubmed publisher

Barbezier N, Chartier A, Bidet Y, Buttstedt A, Voisset C, Galons H, et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med. 2011;3:35-49 pubmed publisher

Marcelín Jiménez G, P Angeles Moreno A, Mendoza Morales L, Rivera Espinosa L, Martínez M. Development of an ultra-performance liquid chromatography-tandem mass spectrometry micromethod for quantification of lamotrigine in human plasma and its use in a bioequivalence trial. Bioanalysis. 2009;1:47-55 pubmed publisher

Gug F, Oumata N, Tribouillard Tanvier D, Voisset C, Desban N, Bach S, et al. Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography. Bioconjug Chem. 2010;21:279-88 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Yuan J, Johnson R, Huang R, Wichterman J, Jiang H, Hayton K, et al. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol. 2009;5:765-71 pubmed publisher

Yuan K, Jin X, Park W, Kim J, Park B, Kim S. Modification of atrial natriuretic peptide system in cold-induced hypertensive rats. Regul Pept. 2009;154:112-20 pubmed publisher

Ibarra Velarde F, Vera Montenegro Y, Huesca Guillen A, Cantó Alarcón G, Alcala Canto Y, Marrero Ponce Y. In silico fasciolicide activity of three experimental compounds in sheep. Ann N Y Acad Sci. 2008;1149:183-5 pubmed publisher

Norez C, Vandebrouck C, Antigny F, Dannhoffer L, Blondel M, Becq F. Guanabenz, an alpha2-selective adrenergic agonist, activates Ca2+-dependent chloride currents in cystic fibrosis human airway epithelial cells. Eur J Pharmacol. 2008;592:33-40 pubmed publisher

Tribouillard Tanvier D, Dos Reis S, Gug F, Voisset C, Beringue V, Sabate R, et al. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS ONE. 2008;3:e2174 pubmed publisher

Tribouillard Tanvier D, Beringue V, Desban N, Gug F, Bach S, Voisset C, et al. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS ONE. 2008;3:e1981 pubmed publisher

Yuan K, Rhee K, Park W, Kim S, Kim S. Different response of ANP secretion to adrenoceptor stimulation in renal hypertensive rat atria. Peptides. 2008;29:1207-15 pubmed publisher

Wilson C, Akhter S, Mayer C, Kc P, Balan K, Ernsberger P, et al. Allergic lung inflammation affects central noradrenergic control of cholinergic outflow to the airways in ferrets. J Appl Physiol (1985). 2007;103:2095-104 pubmed

Sica D. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007;9:399-405 pubmed

Diamandis P, Wildenhain J, Clarke I, Sacher A, Graham J, Bellows D, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol. 2007;3:268-73 pubmed

Colahan P, Savage K, Tebbett I, Rice B, Jackson C, Freshwater L. The effect of adrenergic suppression induced by guanabenz administration on exercising thoroughbred horses. Equine Vet J Suppl. 2006;:262-6 pubmed

Dunbar A, Jenkins G, Jianmongkol S, Nakatsuka M, Lowe E, Lau M, et al. Tetrahydrobiopterin protects against guanabenz-mediated inhibition of neuronal nitric-oxide synthase in vitro and in vivo. Drug Metab Dispos. 2006;34:1448-56 pubmed

Velliquette R, Kossover R, Previs S, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:300-12 pubmed

Clement B, Mau S, Deters S, Havemeyer A. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid). Drug Metab Dispos. 2005;33:1740-7 pubmed

Masse F, Hascoet M, Bourin M. alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice. Behav Brain Res. 2005;164:17-28 pubmed

Holmes B, Brogden R, Heel R, Speight T, Avery G. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1983;26:212-29 pubmed